Quality-Adjusted Survival Analysis of Neurologic Events with Cilta-Cel Versus Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma Who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Surbhi Sidana, Leyla Osman Shune, Luciano J. Costa, Roberto Mina, Rafal Slowik, Jianming He, João Mendes, Jackie Kwong, Maren Gaudig, Seina Lee, Mukta Sharma, Rakesh Popat
+1 more Cyrille Touzeau
DOI: 10.1016/j.jtct.2025.12.251
Cited by: 0

Fields of Study & Subjects

CAR-T cell therapy research Multiple Myeloma Research and Treatments Health Systems Economic Evaluations Quality of Life

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S183–S183
Publication date
1 February 2026
Language
EN